Published in Trends Immunol on March 01, 2004
Modulation of the antitumor immune response by complement. Nat Immunol (2008) 4.53
NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood (2007) 1.69
HER2/neu as a potential target for immunotherapy in gynecologic carcinosarcomas. Int J Gynecol Pathol (2012) 1.55
A targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer. Blood (2012) 1.45
Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. MAbs (2011) 1.27
Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. Breast Cancer Res Treat (2010) 1.19
Preparation, characterization, and biological properties of β-glucans. J Adv Pharm Technol Res (2011) 1.18
Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC. Drug Des Devel Ther (2009) 1.17
Mechanisms of action of CD20 antibodies. Am J Cancer Res (2012) 1.15
The role of complement in tumor growth. Adv Exp Med Biol (2014) 1.11
Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies. Clin Cancer Res (2009) 1.09
Combined yeast {beta}-glucan and antitumor monoclonal antibody therapy requires C5a-mediated neutrophil chemotaxis via regulation of decay-accelerating factor CD55. Cancer Res (2007) 1.09
Inhibition of tumor growth by plant-derived mAb. Proc Natl Acad Sci U S A (2005) 1.08
Combined yeast-derived beta-glucan with anti-tumor monoclonal antibody for cancer immunotherapy. Exp Mol Pathol (2009) 1.07
Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep (2015) 1.03
The pattern of clinical breast cancer metastasis correlates with a single nucleotide polymorphism in the C1qA component of complement. Immunogenetics (2006) 1.00
Down-regulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes tumour cells to complement attack. Clin Exp Immunol (2007) 0.97
The use of lentinan for treating gastric cancer. Anticancer Agents Med Chem (2013) 0.96
Yeast-derived beta-glucan augments the therapeutic efficacy mediated by anti-vascular endothelial growth factor monoclonal antibody in human carcinoma xenograft models. Clin Cancer Res (2008) 0.95
Regulation of the Helicobacter pylori cellular receptor decay-accelerating factor. J Biol Chem (2008) 0.92
Lectin site ligation of CR3 induces conformational changes and signaling. J Biol Chem (2011) 0.91
Modulation of protective T cell immunity by complement inhibitor expression on tumor cells. Cancer Res (2008) 0.90
Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response. PLoS One (2012) 0.90
High-resolution structures of bacterially expressed soluble human CD59. Acta Crystallogr Sect F Struct Biol Cryst Commun (2007) 0.90
Immunostimulatory properties and antitumor activities of glucans (Review). Int J Oncol (2013) 0.89
Functional bioassays for immune monitoring of high-risk neuroblastoma patients treated with ch14.18/CHO anti-GD2 antibody. PLoS One (2014) 0.89
Humoral innate immune response and disease. Clin Immunol (2012) 0.89
Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions. Clin Dev Immunol (2012) 0.88
Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice. Leukemia (2014) 0.82
Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factor. Clin Exp Metastasis (2011) 0.82
Neutralization of membrane complement regulators improves complement-dependent effector functions of therapeutic anticancer antibodies targeting leukemic cells. Oncoimmunology (2015) 0.81
Protein engineering to target complement evasion in cancer. FEBS Lett (2013) 0.80
From tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumors. Clin Dev Immunol (2011) 0.80
Tag SNPs in complement receptor-1 contribute to the susceptibility to non-small cell lung cancer. Mol Cancer (2014) 0.80
Enhanced complement resistance in drug-selected P-glycoprotein expressing multi-drug-resistant ovarian carcinoma cells. Clin Exp Immunol (2008) 0.79
Commandeering a biological pathway using aptamer-derived molecular adaptors. Nucleic Acids Res (2010) 0.78
Complement receptor 1 genetic variants contribute to the susceptibility to gastric cancer in chinese population. J Cancer (2015) 0.76
The dual role of complement in cancer and its implication in anti-tumor therapy. Ann Transl Med (2016) 0.75
Effector attenuating substitutions that maintain antibody stability and reduce toxicity in mice. J Biol Chem (2017) 0.75
A common CD55 rs2564978 variant is associated with the susceptibility of non-small cell lung cancer. Oncotarget (2017) 0.75
Hep88 mAb-initiated paraptosis-like PCD pathway in hepatocellular carcinoma cell line through the binding of mortalin (HSPA9) and alpha-enolase. Cancer Cell Int (2014) 0.75
Complement susceptibility in glutamine deprived breast cancer cells. Cell Div (2007) 0.75
Complement component 7 (C7), a potential tumor suppressor, is correlated with tumor progression and prognosis. Oncotarget (2016) 0.75
Optimizing complement-activating antibody-based cancer immunotherapy: a feasible strategy? J Transl Med (2004) 0.75
Fc receptors and their influence on efficacy of therapeutic antibodies for treatment of viral diseases. Expert Rev Anti Infect Ther (2015) 0.75
Antibody-drug conjugates and other nanomedicines: the frontier of gynaecological cancer treatment. Interface Focus (2016) 0.75
CD55 and CD59 expression protects HER2-overexpressing breast cancer cells from trastuzumab-induced complement-dependent cytotoxicity. Oncol Lett (2017) 0.75
M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J Immunol (2011) 2.02
Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J Immunol (2004) 2.00
Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Res (2003) 1.81
Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J Clin Invest (2005) 1.70
A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J Immunol (2008) 1.70
Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients? Clin Cancer Res (2008) 1.54
A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration. Invest Ophthalmol Vis Sci (2009) 1.54
Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation. J Clin Invest (2003) 1.46
Oxidative stress renders retinal pigment epithelial cells susceptible to complement-mediated injury. J Biol Chem (2009) 1.45
A targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer. Blood (2012) 1.45
Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex genetic alterations in cervical cancer. BMC Genomics (2007) 1.24
Effects of active and inactive phospholipase D2 on signal transduction, adhesion, migration, invasion, and metastasis in EL4 lymphoma cells. Mol Pharmacol (2008) 1.23
A complement-dependent balance between hepatic ischemia/reperfusion injury and liver regeneration in mice. J Clin Invest (2009) 1.21
Essential roles of grp94 in gut homeostasis via chaperoning canonical Wnt pathway. Proc Natl Acad Sci U S A (2013) 1.19
Complement plays an important role in spinal cord injury and represents a therapeutic target for improving recovery following trauma. Am J Pathol (2006) 1.17
Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer. Cancer Res (2005) 1.16
Mapping the intermedilysin-human CD59 receptor interface reveals a deep correspondence with the binding site on CD59 for complement binding proteins C8alpha and C9. J Biol Chem (2011) 1.12
Crystal structure of CD59: implications for molecular recognition of the complement proteins C8 and C9 in the membrane-attack complex. Acta Crystallogr D Biol Crystallogr (2007) 1.11
A complement C3 inhibitor specifically targeted to sites of complement activation effectively ameliorates collagen-induced arthritis in DBA/1J mice. J Immunol (2007) 1.10
Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in mice. J Immunol (2009) 1.09
Complement-dependent P-selectin expression and injury following ischemic stroke. J Immunol (2006) 1.09
Defining the CD59-C9 binding interaction. J Biol Chem (2006) 1.09
Low-dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice. J Immunol (2008) 1.07
C5a-mediated leukotriene B4-amplified neutrophil chemotaxis is essential in tumor immunotherapy facilitated by anti-tumor monoclonal antibody and beta-glucan. J Immunol (2005) 1.07
Function of the lectin domain of Mac-1/complement receptor type 3 (CD11b/CD18) in regulating neutrophil adhesion. J Immunol (2002) 1.07
Targeted inhibition of complement activation prevents features of preeclampsia in mice. Kidney Int (2010) 1.04
The alternative complement pathway propagates inflammation and injury in murine ischemic stroke. J Immunol (2012) 1.03
Pathogenic natural antibodies propagate cerebral injury following ischemic stroke in mice. J Immunol (2011) 1.02
CR2-mediated targeting of complement inhibitors: bench-to-bedside using a novel strategy for site-specific complement modulation. Adv Exp Med Biol (2013) 1.01
Complement inhibitors targeted to the proximal tubule prevent injury in experimental nephrotic syndrome and demonstrate a key role for C5b-9. J Immunol (2005) 1.01
Binding of factor H to tubular epithelial cells limits interstitial complement activation in ischemic injury. Kidney Int (2011) 1.00
Complement regulates TLR4-mediated inflammatory responses during intestinal ischemia reperfusion. Mol Immunol (2010) 0.99
Transforming growth factor-beta1 induces tumor stroma and reduces tumor infiltrate in cervical cancer. Hum Pathol (2002) 0.99
The alternative pathway is required, but not alone sufficient, for retinal pathology in mouse laser-induced choroidal neovascularization. Mol Immunol (2011) 0.98
Expression of Smad2 and Smad4 in cervical cancer: absent nuclear Smad4 expression correlates with poor survival. Mod Pathol (2008) 0.97
The alternative and terminal pathways of complement mediate post-traumatic spinal cord inflammation and injury. Am J Pathol (2010) 0.95
CD4+ T cells and complement independently mediate graft ischemia in the rejection of mouse orthotopic tracheal transplants. Circ Res (2011) 0.94
Insights into the human CD59 complement binding interface toward engineering new therapeutics. J Biol Chem (2005) 0.94
Ketamine-xylazine-acepromazine compared with isoflurane for anesthesia during liver transplantation in rodents. J Am Assoc Lab Anim Sci (2010) 0.93
EMMPRIN-induced MMP-2 activation cascade in human cervical squamous cell carcinoma. Int J Cancer (2006) 0.92
Targeted complement inhibitors protect against posttransplant cardiac ischemia and reperfusion injury and reveal an important role for the alternative pathway of complement activation. J Immunol (2010) 0.92
Upregulated expression of complement inhibitory proteins on bladder cancer cells and anti-MUC1 antibody immune selection. Int J Cancer (2008) 0.92
A tumor-expressed inhibitor of the early but not late complement lytic pathway enhances tumor growth in a rat model of human breast cancer. Cancer Res (2002) 0.92
The C5 convertase is not required for activation of the terminal complement pathway in murine experimental cerebral malaria. J Biol Chem (2012) 0.92
Molecular mechanisms of epidermal growth factor receptor overexpression in patients with cervical cancer. Mod Pathol (2011) 0.91
Prognostic relevance of TGF-beta1 and PAI-1 in cervical cancer. Int J Cancer (2004) 0.91
Modulation of protective T cell immunity by complement inhibitor expression on tumor cells. Cancer Res (2008) 0.90
Targeting complement component 5a promotes vascular integrity and limits airway remodeling. Proc Natl Acad Sci U S A (2013) 0.90
Cervical cancer cell-derived interleukin-6 impairs CCR7-dependent migration of MMP-9-expressing dendritic cells. Int J Cancer (2014) 0.89
The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice. Arthritis Rheum (2011) 0.89
Non-proteolytic, receptor/ligand interactions associate cellular membrane type-1 matrix metalloproteinase with the complement component C1q. J Biol Chem (2004) 0.89
Oral beta-glucan adjuvant therapy converts nonprotective Th2 response to protective Th1 cell-mediated immune response in mammary tumor-bearing mice. Folia Histochem Cytobiol (2007) 0.89
Complement and the alternative pathway play an important role in LPS/D-GalN-induced fulminant hepatic failure. PLoS One (2011) 0.88
The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies. Lab Invest (2002) 0.88
Cellular membrane type-1 matrix metalloproteinase (MT1-MMP) cleaves C3b, an essential component of the complement system. J Biol Chem (2004) 0.87
Mouse complement receptor-related gene y/p65-neutralized tumor vaccine induces antitumor activity in vivo. J Immunol (2004) 0.87
Inhibition of complement activation alleviates acute lung injury induced by highly pathogenic avian influenza H5N1 virus infection. Am J Respir Cell Mol Biol (2013) 0.87
Substantial changes in gene expression of Wnt, MAPK and TNFalpha pathways induced by TGF-beta1 in cervical cancer cell lines. Carcinogenesis (2005) 0.87
Enhancement of the complement activating capacity of 17-1A mAb to overcome the effect of membrane-bound complement regulatory proteins on colorectal carcinoma. Eur J Immunol (2002) 0.86
Complement-dependent injury and protection in a murine model of acute dextran sulfate sodium-induced colitis. J Immunol (2012) 0.86
Role of tumor-derived proinflammatory cytokines GM-CSF, TNF-alpha, and IL-12 in the migration and differentiation of antigen-presenting cells in cervical carcinoma. Cancer (2007) 0.86
Tumor-specific inhibition of membrane-bound complement regulatory protein Crry with bispecific monoclonal antibodies prevents tumor outgrowth in a rat colorectal cancer lung metastases model. Cancer Res (2004) 0.85
FoxP3(+) and IL-17(+) cells are correlated with improved prognosis in cervical adenocarcinoma. Cancer Immunol Immunother (2015) 0.85
Complement inhibition alleviates paraquat-induced acute lung injury. Am J Respir Cell Mol Biol (2011) 0.85
The critical role of complement alternative pathway regulator factor H in allergen-induced airway hyperresponsiveness and inflammation. J Immunol (2011) 0.85
A new therapeutic strategy for lung tissue injury induced by influenza with CR2 targeting complement inhibitor. Virol J (2010) 0.85
Interaction of differently designed immunoliposomes with colon cancer cells and Kupffer cells. An in vitro comparison. Pharm Res (2003) 0.84
Expression of rat complement control protein Crry on tumor cells inhibits rat natural killer cell-mediated cytotoxicity. Blood (2002) 0.84
Interference with the complement system by tumor cell membrane type-1 matrix metalloproteinase plays a significant role in promoting metastasis in mice. Cancer Res (2006) 0.83
Oval cell response is attenuated by depletion of liver resident macrophages in the 2-AAF/partial hepatectomy rat. PLoS One (2012) 0.83
Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement. Cancer Res (2007) 0.83
Inhibition of a complement regulator in vivo enhances antibody therapy in a model of mammary adenocarcinoma. Int J Cancer (2004) 0.82
Complement-dependent inflammation and injury in a murine model of brain dead donor hearts. Circ Res (2009) 0.82
The dual role of complement in the progression of renal disease in NZB/W F(1) mice and alternative pathway inhibition. Mol Immunol (2011) 0.82
Differential expression of FAK and Pyk2 in metastatic and non-metastatic EL4 lymphoma cell lines. Clin Exp Metastasis (2011) 0.81
The role of acid sphingomyelinase and caspase 5 in hypoxia-induced HuR cleavage and subsequent apoptosis in hepatocytes. Biochim Biophys Acta (2012) 0.81
Targeted inhibition of complement using complement receptor 2-conjugated inhibitors attenuates EAE. Neurosci Lett (2012) 0.81
Beta-glucan enhanced killing of renal cell carcinoma micrometastases by monoclonal antibody G250 directed complement activation. Int J Cancer (2004) 0.81
A role for complement in the enhanced susceptibility of steatotic livers to ischemia and reperfusion injury. J Immunol (2009) 0.81
Upregulation of the δ opioid receptor in liver cancer promotes liver cancer progression both in vitro and in vivo. Int J Oncol (2013) 0.80
The effect of dexamethasone on human mucin 1 expression and antibody-dependent complement sensitivity in a prostate cancer cell line in vitro and in vivo. Immunology (2004) 0.80
A targeted inhibitor of the complement alternative pathway reduces RPE injury and angiogenesis in models of age-related macular degeneration. Adv Exp Med Biol (2010) 0.80
Donor brain death exacerbates complement-dependent ischemia/reperfusion injury in transplanted hearts. Circulation (2013) 0.80
Macrophage-produced IL-12p70 mediates hemorrhage-induced damage in a complement-dependent manner. Shock (2011) 0.80
Reduction of myeloid-derived suppressor cells and lymphoma growth by a natural triterpenoid. J Cell Biochem (2015) 0.80
Inhibiting complement regulators in cancer immunotherapy with bispecific mAbs. Expert Opin Biol Ther (2005) 0.79
Highly specific inhibition of C1q globular-head binding to human IgG: a novel approach to control and regulate the classical complement pathway using an engineered single chain antibody variable fragment. Mol Immunol (2008) 0.78
Endothelium specific matrilysin (MMP-7) expression in human cancers. Matrix Biol (2007) 0.78
Cross-linking tumor cells with effector cells via CD55 with a bispecific mAb induces beta-glucan-dependent CR3-dependent cellular cytotoxicity. Eur J Immunol (2006) 0.78
Creating a successful environment for preparing doctoral-level nurse educators. J Nurs Educ (2012) 0.77
Early Application of Auxiliary Partial Orthotopic Liver Transplantation in Murine Model of Wilson Disease. Transplantation (2015) 0.76
Natural immunity to human African trypanosomiasis: trypanosome lytic factors and the blood incubation infectivity test. Trans R Soc Trop Med Hyg (2002) 0.76
A new mouse anti-mouse complement receptor type 2 and 1 (CR2/CR1) monoclonal antibody as a tool to study receptor involvement in chronic models of immune responses and disease. Mol Immunol (2015) 0.75
A novel trifunctional IgG-like bispecific antibody to inhibit HIV-1 infection and enhance lysis of HIV by targeting activation of complement. Virol J (2010) 0.75
Targeted complement inhibition protects vascularized composite allografts from acute graft injury and prolongs graft survival when combined with subtherapeutic cyclosporine A therapy. Transplantation (2016) 0.75
A new treatment for neurogenic inflammation caused by EV71 with CR2-targeted complement inhibitor. Virol J (2012) 0.75
Qualitative Analysis of the Lived Experience of First-Time Nurse Responders in Disaster. J Contin Educ Nurs (2016) 0.75
The emerging Doctor of Education (EdD) in instructional leadership for nurse educators. Int J Nurs Educ Scholarsh (2013) 0.75
Lack of TNFalpha mRNA expression in cervical cancer is not associated with loss of heterozygosity at 6p21.3, inactivating mutations or promoter methylation. Mol Immunol (2007) 0.75